Paricalcitol for reduction of albuminuria in diabetes
Albeit based on robust methods, the study by Dick de Zeeuw and colleagues (Nov 6, p 2010) 1 raises several concerns. First, little attention is given to the fact that the primary endpointie, the eff ect of the vitamin D receptor activator (VDRA) on urinary albuminto-creatinine ratio (UACR)-is actually negative. The positive results on secondary endpoints should thus be used only to generate new hypotheses, not to support the effi cacy of the intervention. Besides, any reduction in UACR must also be interpreted in the context of its biological variation in patients with diabetes, which is estimated at 61%. 2 Second, the mean concentration of vitamin D in the patients included (40 nmol/L) is far below the current recommendations 3, 4 and refl ects a severe defi ciency. Subgroup analysis according to the 25-hydroxyvitamin D concentration would be of interest.
Third, the cost-eff ectiveness of a strategy based on paricalcitol in this indication has to be balanced with the use of the much cheaper native vitamin D for which there are physiological reasons to expect some effi cacy. 5 Finally, the long-term safety of this strategy is questionable. Paricalcitol logically decreased concentrations of parathyroid hormone (from 90·7 to 40 μg/L in the 2 μg group). These supraphysiological doses of selective VDRA could increase the risk of low bone turnover (with the inherent increased risk of vascular calcifi cations). Data on calciuria would be valuable in this regard. Risk of renal stones or nephrocalcinosis in the long term should also be discussed.
We declare that we have no confl icts of interest. In the VITAL study, 1 Dick de Zeeuw and colleagues conclude that paricalcitol could be a novel approach to lower residual albuminuria and renal risk in patients with diabetes. However, several facts undermine this suggestion.
First, the reduction in urinary albuminto-creatinine ratio (UACR) from baseline to last measurement did not reach signifi cance (p=0·053). Second, the proportion of patients who achieved at least a 15% UACR reduction in the same time would be non-signifi cant if only one additional patient from the 2 μg paricalcitol group had not met this goal. Third, it seems that a relatively high paricalcitol dose (2 μg/day) is needed for any antiproteinuric eff ect to be shown since the 1 μg group did not have such an eff ect. Of note, the 2 μg group had a signifi cantly higher dropout rate owing to adverse events than the 1 μg and placebo groups, and all three deaths in the study occurred in the 2 μg group. Finally, although signifi cant, the small reduction (254 mg) in the mean 24-h urinary albumin between baseline and the last measurement in the 2 μg group cannot be regarded as clinically signifi cant until the emergence of larger and longer-duration random ised controlled trials to assess hard endpoints such as renal or overall survival.
In my opinion the use of high-dose paricalcitol for the prevention of renal damage in patients with diabetes and chronic kidney disease is of uncertain effi ciency and safety and thus should not be recommended on the basis of the current data. Dick de Zeeuw and colleagues 1 report that oral admini stration of 2 μg/day paricalcitol for 24 weeks safely lowers residual albuminuria in patients treated with inhibitors of the reninangiotensin-aldosterone system for diabetic nephropathy.
Although de Zeeuw and colleagues provide a wide range of data, they do not report serum phosphorus concentrations during the 24 weeks of paricalcitol administration. Since observational studies have shown that higher concentrations correlate with mortality in diabetic populations with and without renal disease, 2, 3 their value might be of extreme importance.
Another issue that also needs underlining is that diabetic patients with end-stage renal disease (ESRD) often have low-turnover bone disease. Long-term paricalcitol administration during the months or years before reaching ESRD might aggravate adynamic bone disease (a diffi cult-toreverse form of renal bone disease) in diabetic patients who will eventually need dialysis.
Despite the encouraging results of de Zeuuw and colleagues' study, longterm clinical trials with oral paricalcitol in patients with diabetes and renal disease are urgently warranted, and with more meaningful endpoints such as mortality or ESRD.
I declare that I have no confl icts of interest. 
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Authors' reply
The VITAL study reported that paricalcitol lowers albuminuria in patients with type 2 diabetes and residual high albuminuria after guideline therapy, including an inhibitor of the renin-angiotensinaldosterone system. The reason why we interpreted the antialbuminuric data with somewhat more confi dence than do Pierre Delanaye and colleagues and Theodoros Kassimatis has to do with the fact that paricalcitol's eff ect (in particular the 2 μg dose) is highly signifi cant when looking at 24-h urine albuminuria, and looking at urinary albumin-to-creatinine ratio (UACR) eff ects over all timepoints available. As mentioned by Delanaye and colleagues and Kassimatis, the eff ect size and the power of the study are not high, and we fully agree that VITAL is a hypothesis-generating study with a strong argument to do a fi nal study on hard renal endpoints.
We thank Alberto Ortiz and colleagues for calling attention to the fact that most patients with chronic kidney disease (CKD) are vitamin D defi cient. This point makes it im possible to assess the effi cacy of paricalcitol in those who were vitamin D replete. As mentioned in our Article, a study with calcitriol did also show modest antiproteinuric eff ects in IgA nephropathy.
1 Future comparative studies should establish whether the eff ect of raising 25-hydroxyvitamin D concentrations with cholecalciferol or ergocalciferol can reduce albuminuria to a similar extent to paricalcitol.
Regarding paricalcitol dose reductions in our trial, the protocol specifi ed that patients would have dose reductions in the event of oversup pres sion of parathyroid hormone or of hypercalcaemia. The fi nding that dose reductions occurred in 42% of patients in the 2 μg group indicates that the majority were able to receive high-dose paricalcitol throughout. The 2 μg group did show the antialbuminuric eff ects despite this down-titration.
Although we agree with Costas Fourtounas that observational studies in CKD patients have shown associations between higher serum phosphate concentrations and increased mortality in patients who are mostly vitamin D defi cient, 2 Second, the potential adverse eff ects of paricalcitol on mineral metabolism are not carefully documented. Apparently there were no pre-estab lished criteria for dose reduction. Thus we wonder what triggered dose reduction in patients assigned to 2 μg/day, what were serum calcium and phosphate concentrations at the time of dose reduction, and whether additional biochemical abnormalities were present in patients with sup pressed parathyroid hormone con centrations.
Finally, the eff ect of pari calcitol on serum phosphate concentrations or phosphate binder use is con spicuously missing.
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